Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
OwnerMichael D. Schneider, Motoaki Sanoinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the field of cardiology. More particularly, the present invention relates to methods of using inhibitors of cyclin dependent kinase 9 (Cdk9) to treat cardiovascular disease by blunting cardiac hypertrophy.
Claims42
A method of treating a subject suffering from a cardiovascular disease comprising the step of administering to the subject an effective amount of a composition to modulate cyclin dependent kinase 9 (Cdk9) activity, wherein the effective amount modulates hypertrophic growth.
A method of modulating myocyte enlargement in a subject at risk for cardiac hypertrophy comprising the steps of administering to the subject an effective amount of a composition to modulate cyclin dependent kinase 9 (Cdk9) activity, wherein the effective amount modulates myocyte enlargement.
A method of modulating cardiac hypertrophy comprising the step of administering to a subject an effective amount of a composition to modulate cyclin dependent kinase 9 (Cdk9) activity, wherein the effective amount modulates hypertrophic growth.
A method of treating heart failure comprising the step of administering to a subject an effective amount of a composition to modulate cyclin dependent kinase 9 (Cdk9) activity.
A method of modulating a decrease in cardiac muscle contractile strength in a subject comprising the step of administering to the subject an effective amount of a composition to modulate cyclin dependent kinase 9 (Cdk9) activity, wherein the effective amount modulates the decrease in cardiac muscle contractile strength.
A method of treating a subject at risk for ventricular dysfunction associated with cardiac hypertrophy comprising the steps of administering to the subject an effective amount of a composition to modulate cyclin dependent kinase 9 (Cdk9) activity, wherein the effective amount decreases ventricular dysfunction.
A method of screening for a modulator of cyclin-dependent kinase 9 (Cdk9) comprising:
- obtaining Cdk9;
- contacting the Cdk9 with a candidate substance;
- and
- assaying for Cdk9 activity, wherein when the Cdk9 activity changes after the contacting, the candidate substance is a modulator of Cdk9.
A method of modulating cardiomyocyte apoptosis in a subject at risk or having a cardiovascular disease comprising the step of administering to the subject a therapeutically effective amount of a composition that modulates mitochondrial function.
A method of treating heart failure in a subject comprising administering a therapeutically effective amount of an anti-apoptotic composition to the subject.
Dependencies are inferred from the claim text.